Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Randomized, Double-blind, Placebo- and Moxifloxacin-controlled, Phase 1 Study to Assess the Effect of Single Therapeutic and Supratherapeutic Doses of Daridorexant on the QT Interval Duration in Healthy Subjects

Next Previous
Trial Profile

A Single-center, Randomized, Double-blind, Placebo- and Moxifloxacin-controlled, Phase 1 Study to Assess the Effect of Single Therapeutic and Supratherapeutic Doses of Daridorexant on the QT Interval Duration in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Aug 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daridorexant (Primary) ; Moxifloxacin
  • Indications Insomnia; Sleep apnoea syndrome
  • Focus Adverse reactions
  • Sponsors Idorsia Pharmaceuticals

Most Recent Events

  • 31 Jul 2021 Results investigating the effect of daridorexant at a therapeutic and supratherapeutic dose on QT interval duration, published in the Clinical Drug Investigation
  • 02 Sep 2020 Status changed from active, no longer recruiting to completed.
  • 30 Jun 2020 Planned End Date changed from 17 Jun 2020 to 16 Jul 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top